Blog
RSS FeedPosted by Michael Wonder on 27 May 2019
Breast cancer treatments, rare disorders, venlafaxine
27 May 2019 - PHARMAC has published more information on its decisions on the funding of medicines for breast cancer, ...
Posted by Michael Wonder on 22 May 2019
Extending VBP models into Medicaid drug purchasing: challenges and opportunities
22 May 2019 - Over the past decade, both public and private payers have increasingly sought to develop payment policies that ...
Posted by Michael Wonder on 14 May 2019
PHARMAC publishes list of applications to be considered by PTAC later this month
14 May 2019 - The list includes a number of medicines for patients with breast cancer. ...
Posted by Michael Wonder on 14 May 2019
Analysis of sponsor hearings on PBAC decision making
14 May 2019 - Original research conducted by Melinda Flowers, Sean Lybrand and myself has been published on-line in the ...
Posted by Michael Wonder on 02 May 2019
ICER seeks public input for 2020 value assessment framework
2 May 2019 - Accepting Open Input Through 10 June 2019. ...
Posted by Michael Wonder on 01 May 2019
PHARMAC sheds a little more light on procedures in savvy political move
1 May 2019 - Steve Maharey has just secured special status on David Clark's Christmas card list. ...
Posted by Michael Wonder on 29 Apr 2019
The obscure advisory committees at the heart of the U.S. drug pricing debate
30 April 2019 - Expectations were high last year for three new migraine drugs hitting the market from Amgen, Eli Lilly ...
Posted by Michael Wonder on 29 Apr 2019
Proposal to decline inactive applications
29 April 2019 - To help make its decision-making process clearer, PHARMAC is seeking feedback on a proposal to make ...
Posted by Michael Wonder on 29 Apr 2019
PHARMAC proposes to give more clarity about funding decisions
29 April 2019 - An overhaul of PHARMAC’s decision-making process will give better insight into what medicines are - and ...
Posted by Michael Wonder on 12 Apr 2019
Addressing health system values in health technology assessment: the use of evidence-informed deliberative processes
8 April 2019 - Health technology assessment is increasingly used around the globe to inform resource allocation decisions. Furthermore, the importance ...
Posted by Michael Wonder on 08 Apr 2019
Value-based agreements could disrupt how we pay for new therapies
8 April 2019 - On Tuesday, the Senate Finance Committee will hold its second hearing in a series on drug ...
Posted by Michael Wonder on 08 Apr 2019
Greater flexibility needed by PHARMAC to fund new medicines, including cancer drug - expert
8 April 2019 - The fight continues in New Zealand for funding of a life-prolonging drug that targets advanced breast ...
Posted by Michael Wonder on 07 Apr 2019
Don’t attack NICE for relying on facts instead of emotion
3 April 2019 - The National Institute for Health and Care Excellence marks its 20th anniversary this week. ...
Posted by Michael Wonder on 28 Mar 2019
Keeping up the PACE at the Scottish Medicines Consortium
26 March 2019 - There are many ways that patient centricity could be delivered when doing a health technology assessment. ...
Posted by Michael Wonder on 26 Mar 2019
Cancer Society critical of PHARMAC saying they 'lack accountability, lack transparency, are slow'
26 March 2019 - PHARMAC "lack accountability, lack transparency, are slow", in delivering pharmaceutical drugs to New Zealanders who need ...